The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals announced its financial results for the third quarter of 2026, along with an update on its clinical development program and business priorities.
The statement provides a snapshot of the companys latest earnings period and reflects ongoing work in ophthalmology through its clinical pipeline. Further details were not disclosed in the statement provided.
View post on X Loading...
Earlier this year, Eyepoint Pharmaceuticals released topline results from its second pivotal Phase 3 LUCIA trial for DURAVYU in wet AMD, according to a previous statement. The company continues to focus on advancing its ophthalmology pipeline. This follows its ongoing work in clinical development and quarterly financial reporting.